To the full analysis
Sino Biopharmaceutical stock: growth
1177.HKSino Biopharmaceutical reported $4.77B in revenue for fiscal 2025, up 10.3% on the prior year, up 6.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
21.9%
per year from 2006 to 2025, per share 20.9%
Earnings (Annual rate)
15.9%
per year from 2006 to 2025, per share 14.9%
Free cash flow (Annual rate)
31.4%
per year from 2006 to 2025, per share 30.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.1% | 10.1% | 21.9% |
| Revenue per share | 7.0% | 9.2% | 20.9% |
| Earnings | −3.3% | 4.6% | 15.9% |
| Earnings per share | −2.8% | 3.8% | 14.9% |
| Free cash flow | 17.0% | 25.2% | 31.4% |
| Free cash flow per share | 17.9% | 24.3% | 30.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $110.47M | $21.23M | $6.36M |
| 2007 | $169.94M | $31.52M | $23.71M |
| 2008 | $301.35M | $39.3M | $27.04M |
| 2009 | $428.28M | $52.41M | $43.91M |
| 2010 | $522.22M | $72.45M | $16.45M |
| 2011 | $701.8M | $56.17M | $96.35M |
| 2012 | $905.25M | $107.56M | $145.3M |
| 2013 | $1.16B | $121.49M | $116.39M |
| 2014 | $1.48B | $181.46M | $199.28M |
| 2015 | $1.83B | $223.36M | $119.78M |
| 2016 | $2.03B | $245.55M | $323.26M |
| 2017 | $2.22B | $325.56M | $340.77M |
| 2018 | $3.13B | $1.36B | $510.12M |
| 2019 | $3.63B | $414.13M | $538.47M |
| 2020 | $3.55B | $415.56M | $519.8M |
| 2021 | $4.03B | $2.19B | $520.72M |
| 2022 | $3.9B | $381.44M | $683.77M |
| 2023 | $3.93B | $349.71M | $654.15M |
| 2024 | $4.33B | $524.85M | $782.96M |
| 2025 | $4.77B | $351.42M | $1.14B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 16 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.